AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AMPLIA THERAPEUTICS LTD

0.110

0.000

Volume:60.38K

Turnover:6.64K

Market Cap:56.44M

PE:-5.46

High:0.110

Open:0.110

Low:0.110

Close:0.110

52wk High:0.425

52wk Low:0.049

Shares:513.07M

Float Shares:351.32M

Volume Ratio:0.14

T/O Rate:0.02%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.020

EPS(LYR):-0.021

ROE:-28.49%

ROA:-17.71%

PB:1.31

PE(LYR):-5.14

Loading ...

Overview Company News Filings

BRIEF-Amplia Therapeutics Announces Appointment Of Hamish George As CFO

Amplia Therapeutics Appoints CFO; Shares Fall 8%

MT Newswires Live

Amplia Therapeutics Ltd-Appointment of Chief Financial Officer

THOMSON REUTERS

Amplia Therapeutics Ltd-Amplia Emergence 2026 Conference Presentation

THOMSON REUTERS

Amplia Therapeutics Announces Opening of US Sites for Amplicity Pancreatic Cancer Trial

THOMSON REUTERS

Amplia Therapeutics Opens Two Sites for Pancreatic Cancer Trial Enrollment; Shares Rise 4%

MT Newswires Live

Amplia Therapeutics Secures Key US Patent for Narmafotinib, Extending Protection to 2040

Amplia Therapeutics Produces Around 13 Kilograms of Cancer Treatment Drug Candidate For Use in Clinical Trials, Shares Jump 7%

MT Newswires Live

Ribomic Files Patent for Anti-Autotaxin Aptamer RBM-006

MT Newswires Live

Amplia Therapeutics Reports Promising Phase 2a Trial Results for Narmafotinib in Pancreatic Cancer

Amplia Therapeutics Announces Phase 2a Results for Narmafotinib in Metastatic Pancreatic Cancer Trial

BRIEF-Amplia Enters Into Second Agreement With Korean Drug Screening Company Next&Bio

Amplia Enters Into Second Agreement With Korean Specialist Drug Screening Company Next&Bio to Explore Combination Therapy With Fak Inhibitor and Kras Inhibitors

THOMSON REUTERS

Amplia Therapeutics Enters Second Phase of Research Collaboration with South Korean Preclinical Drug Screening Firm

MT Newswires Live

Is Amplia Therapeutics (ASX:ATX) In A Good Position To Deliver On Growth Plans?

Simply Wall St.

Amplia Therapeutics Reports 35% Response Rate in ACCENT Pancreatic Cancer Trial

BRIEF-Amplia Therapeutics Key Narmafotinib Patent Granted In U.S.

Amplia Therapeutics Ltd: Key Narmafotinib Patent Granted in U.S.

THOMSON REUTERS

Amplia Therapeutics Secures Key US Patent for Cancer Drug Candidate

MT Newswires Live

BUZZ-Australia's Amplia Therapeutics falls as HY loss widens

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ATX.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ATX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ATX.AU\",,,,,undefined,":{"symbol":"ATX.AU","market":"AU","secType":"STK","nameCN":"AMPLIA THERAPEUTICS LTD","latestPrice":0.11,"timestamp":1772766770739,"preClose":0.11,"halted":0,"volume":60384,"delay":0,"changeRate":0,"nameEN":"AMPLIA THERAPEUTICS LTD","floatShares":351321835,"shares":513071629,"eps":-0.020164,"marketStatus":"Trading","change":0,"latestTime":"03-06 14:17:40 AEDT","open":0.11,"high":0.11,"low":0.11,"amount":6642,"amplitude":0,"askPrice":0.115,"askSize":150142,"bidPrice":0.11,"bidSize":115722,"shortable":3,"etf":0,"ttmEps":-0.020164,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1772773200000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.11,"openAndCloseTimeList":[[1772751600000,1772773200000]],"volumeRatio":0.139973,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ATX.AU\",,,,,undefined,":{"symbol":"ATX.AU","floatShares":351321835,"roa":"-17.71%","roe":"-28.49%","lyrEps":-0.021392,"volumeRatio":0.139973,"shares":513071629,"dividePrice":0,"high":0.11,"amplitude":0,"preClose":0.11,"low":0.11,"week52Low":0.049,"pbRate":"1.31","psRate":"11.27","week52High":0.425,"institutionHeld":0,"latestPrice":0.11,"committee":-0.129465,"eps":-0.020164,"divideRate":0,"volume":60384,"delay":0,"ttmEps":-0.020164,"open":0.11,"prevYearClose":0.15,"prevWeekClose":0.12,"prevMonthClose":0.12,"prevQuarterClose":0.15,"fiveDayClose":0.12,"twentyDayClose":0.12,"sixtyDayClose":0.122,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATX.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-04-18","symbol":"ATX.AU","defaultRemindTime":1713398400000,"type":"split","dateTimestamp":1713362400000,"forFactor":971896,"toFactor":1000000,"ratio":0.971896}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATX.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2614773118","title":"BRIEF-Amplia Therapeutics Announces Appointment Of Hamish George As CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2614773118","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614773118?lang=en_us&edition=fundamental","pubTime":"2026-02-25 10:26","pubTimestamp":1771986389,"startTime":"0","endTime":"0","summary":"BRIEF-Amplia Therapeutics Announces Appointment Of Hamish George As CFOFeb 25 (Reuters) - Amplia Therapeutics Ltd ATX.AX:APPOINTMENT OF HAMISH GEORGE AS CHIEF FINANCIAL OFFICERFurther company coverage: ATX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nTUEBN3MBJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATX.AU","BK7067"],"gpt_icon":0},{"id":"2614727304","title":"Amplia Therapeutics Appoints CFO; Shares Fall 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614727304","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614727304?lang=en_us&edition=fundamental","pubTime":"2026-02-25 08:57","pubTimestamp":1771981024,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics (ASX:ATX) has appointed Hamish George as chief financial officer, succeeding Tim Luscombe, effective Wednesday, according to a same-day filing with the Australian bourse.The company's shares fell around 8% in recent Wednesday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","ATX.AU","BK4139","BK4007","BK4539","LENZ"],"gpt_icon":0},{"id":"2614826728","title":"Amplia Therapeutics Ltd-Appointment of Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2614826728","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614826728?lang=en_us&edition=fundamental","pubTime":"2026-02-25 05:10","pubTimestamp":1771967423,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUEBN3MBJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATX.AU","BK7067"],"gpt_icon":0},{"id":"2612460440","title":"Amplia Therapeutics Ltd-Amplia Emergence 2026 Conference Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2612460440","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612460440?lang=en_us&edition=fundamental","pubTime":"2026-02-18 05:13","pubTimestamp":1771362815,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUE13F13T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATX.AU"],"gpt_icon":0},{"id":"2610195873","title":"Amplia Therapeutics Announces Opening of US Sites for Amplicity Pancreatic Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2610195873","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610195873?lang=en_us&edition=fundamental","pubTime":"2026-02-11 21:45","pubTimestamp":1770817500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA9G2LJZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATX.AU","BK7067"],"gpt_icon":0},{"id":"2610260366","title":"Amplia Therapeutics Opens Two Sites for Pancreatic Cancer Trial Enrollment; Shares Rise 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610260366","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610260366?lang=en_us&edition=fundamental","pubTime":"2026-02-11 09:02","pubTimestamp":1770771722,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics  said it opened two sites in the US, which will shortly start recruitment activities for its Amplicity trial, according to a Wednesday filing with the Australian bourse.The trial will evaluate the company's lead drug, narmafotinib, in advanced pancreatic cancer patients, the filing said.An additional three sites in the US will be initiated in the near future as recruitment continues, the filing added.Shares of the company rose past 4% in recent Wednesday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ATX.AU","BK4539","BK4139","LENZ","BK7067","BK4007"],"gpt_icon":0},{"id":"2607046551","title":"Amplia Therapeutics Secures Key US Patent for Narmafotinib, Extending Protection to 2040","url":"https://stock-news.laohu8.com/highlight/detail?id=2607046551","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607046551?lang=en_us&edition=fundamental","pubTime":"2026-01-30 21:45","pubTimestamp":1769780710,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics Ltd. announced that a key patent covering the specific salt and crystal form of narmafotinib used in clinical trials has been granted by the US Patent and Trademark Office. The patent extends protection of the developed form of narmafotinib out to at least 2040 in the US and other jurisdictions where the patent has also been granted, including Europe, Japan, India, and Australia.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amplia Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire  on January 30, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nNDL9lL1VJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2210150020.SGD","BK4588","BK4585","BK7067","LU0314104364.USD","NDAQ","SG9999014005.SGD","IE00BKPKM429.USD","BK4112","SG9999014021.USD","ATX.AU","LU2095319765.USD","SG9999014013.SGD","SG9999014039.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2605430773","title":"Amplia Therapeutics Produces Around 13 Kilograms of Cancer Treatment Drug Candidate For Use in Clinical Trials, Shares Jump 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605430773","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605430773?lang=en_us&edition=fundamental","pubTime":"2026-01-22 09:41","pubTimestamp":1769046106,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics (ASX:ATX) produced around 13 kilograms of its narmafotinib drug candidate for the treatment of cancer to the required purity and quality specifications after the completion of a la","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ATX.AU","BK4539","BK7067","BK4139","BK4007","LENZ"],"gpt_icon":0},{"id":"2603986426","title":"Ribomic Files Patent for Anti-Autotaxin Aptamer RBM-006","url":"https://stock-news.laohu8.com/highlight/detail?id=2603986426","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603986426?lang=en_us&edition=fundamental","pubTime":"2026-01-14 15:44","pubTimestamp":1768376683,"startTime":"0","endTime":"0","summary":"Ribomic  has filed a new substance patent for RBM-006, a highly active anti-autotaxin  aptamer, highlighting its therapeutic potential in a mouse model of diabetic retinopathy, according to a Wednesday filing on the Tokyo Stock Exchange.RBM-006, developed in collaboration with the University of Tokyo's Department of Ophthalmology, demonstrated significant suppression of retinal hemorrhage in mice. The aptamer, which surpasses existing anti-ATX candidates in activity and has a shorter chain length, is being investigated for ophthalmic conditions including glaucoma and age-related macular degeneration.With anti-VEGF therapies ineffective in over half of patients, Ribomic sees RBM-006 as a potential alternative treatment. The company plans to explore early commercialization through partnerships and continues to fund development as scheduled.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","ATX.AU"],"gpt_icon":0},{"id":"2602543397","title":"Amplia Therapeutics Reports Promising Phase 2a Trial Results for Narmafotinib in Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2602543397","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602543397?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:45","pubTimestamp":1768225509,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics Ltd. has announced the presentation of interim data from its ongoing Phase 2a ACCENT trial in metastatic pancreatic cancer at the 2026 ASCO Gastrointestinal Cancer Symposium. The trial evaluates the efficacy and safety of Amplia’s FAK inhibitor, narmafotinib, in combination with standard chemotherapy. The updated data show a progression-free survival of 7.7 months compared to 5.5 months for gemcitabine and Abraxane alone. The overall response rate is reported at 35%, increasing to 42% when including unconfirmed responses. Narmafotinib was found to be well tolerated, with an adverse effect profile similar to chemotherapy alone. The results were shared in a poster presentation and a copy is available on the company’s website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL2TLXkw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","LU0314104364.USD","BK4585","BK4588","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU2095319765.USD","BK7067","IE00BKPKM429.USD","NDAQ","SG9999014013.SGD","ATX.AU","IE00B64PRP62.GBP","SG9999014039.USD","SG9999014005.SGD","LU2210149790.SGD","SG9999014021.USD"],"gpt_icon":0},{"id":"2593413368","title":"Amplia Therapeutics Announces Phase 2a Results for Narmafotinib in Metastatic Pancreatic Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2593413368","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593413368?lang=en_us&edition=fundamental","pubTime":"2025-12-23 21:45","pubTimestamp":1766497512,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics Limited has announced that its Chief Medical Officer, Dr. Jason Lickliter, will present updated results from the ongoing ACCENT trial at the 2026 ASCO Gastrointestinal Cancers Symposium, scheduled for January 8-10, 2026, in San Francisco. The poster, titled \"Narmafotinib  in combination with gemcitabine and nab-paclitaxel as first-line treatment for patients with metastatic pancreatic cancer : Phase 2a results,\" will be presented on Friday, January 9, 2026. The full abstract will be published at 5pm US ET on January 5, 2026. Narmafotinib  is a focal adhesion kinase  inhibitor being evaluated in combination with chemotherapy for metastatic pancreatic cancer. The company is also conducting studies of narmafotinib with FOLFIRINOX in advanced pancreatic cancer patients in Australia and the United States.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL8h9HNh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATX.AU","IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014013.SGD","BK4112","IE00BGHQF748.EUR","NDAQ","BK4585","LU2210150020.SGD","SG9999014005.SGD","BK4588","SG9999014039.USD","LU2210149790.SGD","LU0314104364.USD","SG9999014021.USD","IE00B3QW5Z07.USD","BK7067","LU2095319765.USD"],"gpt_icon":0},{"id":"2592160049","title":"BRIEF-Amplia Enters Into Second Agreement With Korean Drug Screening Company Next&Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2592160049","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592160049?lang=en_us&edition=fundamental","pubTime":"2025-12-19 22:25","pubTimestamp":1766154334,"startTime":"0","endTime":"0","summary":"BRIEF-Amplia Enters Into Second Agreement With Korean Drug Screening Company Next&Bio Dec 19 (Reuters) - Amplia Therapeutics Ltd ATX.AX:AMPLIA ENTERS INTO SECOND AGREEMENT WITH KOREAN SPECIALIST DRUG ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nTUA357RCR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATX.AU","BK7067"],"gpt_icon":0},{"id":"2592016715","title":"Amplia Enters Into Second Agreement With Korean Specialist Drug Screening Company Next&Bio to Explore Combination Therapy With Fak Inhibitor and Kras Inhibitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2592016715","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592016715?lang=en_us&edition=fundamental","pubTime":"2025-12-19 21:45","pubTimestamp":1766151900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nTUA357RCR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATX.AU","BK7067"],"gpt_icon":0},{"id":"2592136767","title":"Amplia Therapeutics Enters Second Phase of Research Collaboration with South Korean Preclinical Drug Screening Firm","url":"https://stock-news.laohu8.com/highlight/detail?id=2592136767","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592136767?lang=en_us&edition=fundamental","pubTime":"2025-12-19 09:54","pubTimestamp":1766109250,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics  entered into the second phase of a research collaboration with South Korean preclinical drug screening company Next & Bio, according to a Friday Australian bourse filing.The firms are collaborating on investigating the ability of Amplia's FAK inhibitors to suppress the growth of patient-derived pancreatic cancer cells that possess genetic mutations in the kRAS gene, which are known to be present in over 90% of pancreatic cancers.Amplia's FAK inhibitor narmafotinib showed promising activity in initial tests, per the filing. Further studies investigating the activity of a combination of narmafotinib with known inhibitors of the mutant kRAS gene will be conducted.Its shares rose 2% in recent trading on Friday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4007","BK4139","BK7067","ATX.AU","BK4539"],"gpt_icon":0},{"id":"2591603387","title":"Is Amplia Therapeutics (ASX:ATX) In A Good Position To Deliver On Growth Plans?","url":"https://stock-news.laohu8.com/highlight/detail?id=2591603387","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591603387?lang=en_us&edition=fundamental","pubTime":"2025-12-16 07:28","pubTimestamp":1765841309,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, although...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-atx/amplia-therapeutics-shares/news/is-amplia-therapeutics-asxatx-in-a-good-position-to-deliver","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-atx/amplia-therapeutics-shares/news/is-amplia-therapeutics-asxatx-in-a-good-position-to-deliver","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ATX.AU","BK7067"],"gpt_icon":0},{"id":"2590501763","title":"Amplia Therapeutics Reports 35% Response Rate in ACCENT Pancreatic Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2590501763","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590501763?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:45","pubTimestamp":1765547111,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics Ltd. announced updated results from its ongoing ACCENT trial investigating its FAK inhibitor narmafotinib in combination with gemcitabine and nab-paclitaxel for metastatic pancreatic cancer. An additional confirmed partial response has been recorded, raising the trial's confirmed objective response rate to 35% , compared to the 23% objective response rate reported for gemcitabine and nab-paclitaxel alone in the benchmark MPACT trial. These updated data were presented by Amplia CEO Dr. Chris Burns at the Life Sciences Virtual Investor Forum on December 11.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amplia Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire  on Decem","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL2ZMKlv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014013.SGD","LU0314104364.USD","BK4588","NDAQ","LU2095319765.USD","ATX.AU","IE00BKPKM429.USD","SG9999014021.USD","SG9999014039.USD","BK4585","SG9999014005.SGD","LU2210150020.SGD","BK7067"],"gpt_icon":0},{"id":"2588752041","title":"BRIEF-Amplia Therapeutics Key Narmafotinib Patent Granted In U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2588752041","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588752041?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:58","pubTimestamp":1764770313,"startTime":"0","endTime":"0","summary":"BRIEF-Amplia Therapeutics Key Narmafotinib Patent Granted In U.S.Dec 3 (Reuters) - Amplia Therapeutics Ltd ATX.AX:AMPLIA THERAPEUTICS LTD: KEY NARMAFOTINIB PATENT GRANTED IN U.S.Source text: ID:nGNX4bMQBbFurther company coverage: ATX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X818F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATX.AU","BK7067"],"gpt_icon":0},{"id":"2588304114","title":"Amplia Therapeutics Ltd: Key Narmafotinib Patent Granted in U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2588304114","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588304114?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:48","pubTimestamp":1764769733,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X818F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATX.AU"],"gpt_icon":0},{"id":"2588306122","title":"Amplia Therapeutics Secures Key US Patent for Cancer Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2588306122","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588306122?lang=en_us&edition=fundamental","pubTime":"2025-12-03 06:25","pubTimestamp":1764714300,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics  received formal approval from the US Patent and Trademark Office for a patent covering a salt and crystal form of its cancer drug candidate, narmafotinib, being developed clinically, according to a Wednesday Australian bourse filing.The patent, allowed in September, has been granted in major markets such as Europe, Japan, India, Korea, and Australia, securing narmafotinib's protection until at least 2040, with other regions still under review, the filing added.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4007","BK7067","BK4539","ATX.AU","BK4139"],"gpt_icon":0},{"id":"2586027243","title":"BUZZ-Australia's Amplia Therapeutics falls as HY loss widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2586027243","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586027243?lang=en_us&edition=fundamental","pubTime":"2025-11-28 10:56","pubTimestamp":1764298591,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Amplia Therapeutics falls as HY loss widens** Shares of Amplia Therapeutics ATX.AX fall 3.6% to A$0.135, on track for their weakest session since November 18** The clinical-stage, dru","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nL6N3X4048:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ATX.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":28,"code":"91000000","status":"200"}]}}